• Cardiac morbidities within 12 mo (congestive heart failure, myocardial infarction, unstable angina, uncontrolled arrhythmias) • Peripheral neuropathy ≥ Grade 2 Evaluable Patients: All pts who started therapy and for whom we are able to assess PFS status at 6 mo.
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Statistical Considerations:
In pts with untreated HER2+ MBC treated with paclitaxel and trastuzumab, median time to progression was 7.4 mo. 8 Due to inclusion of pts with 1 prior treatment in our study, a target 6 mo progression-free rate of ≥ 65% was considered promising, and <50% considered unpromising. For a single stage design, 69 pts were required, at an alpha level of 5% and 80% power.
Based on previous studies, we considered symptomatic CHF rate of ≤4%, 9 and asymptomatic LVEF decline (of ≥ 10% to LVEF <50%) rate of ≤ 20% as acceptable. Grade 3 Peripheral Neuropathy 2 Paclitaxel was held for 6 weeks in one pt, and the paclitaxel dose was reduced in the other pt. Both resolved to grade 1 within 6 weeks.
Grade 3 Neutropenia 1 Paclitaxel dose and frequency were decreased for ANC 600. Given filgrastim. No fever.
Grade 3 Cellulitis and Edema
1 Lower extremity cellulitis and edema. Hospitalized for IV antibiotics. Not neutropenic. Paclitaxel was discontinued.
Grade 3 Dry Skin 1 Triamcinolone cream for dry skin. Polysporin ointment to Grade 2 ulcers. Pt withdrew from the study due to toxicity. Resolved to Grade 1 within 4 weeks.
Grade 3 Blurry Vision 1 Cystic macular degeneration in a pt with prior prolonged paclitaxel. Paclitaxel was held.
• Preliminary results of this single-center phase II study of pts with HER2+ MBC treated with pertuzumab, trastuzumab, and weekly paclitaxel in the first-or second-line setting show that 76% of evaluable pts are progression-free at 6 months.
• Accrual is ongoing, with no unexpected toxicities or cardiac events to date. 
Efficacy at 6 months

Cardiac Toxicity
• No cardiac events as of 11/12/12.
• One pt had asymptomatic LVEF decline (Grade 2). EF declined from 57% to 47% at 9 mo in a 61 year old woman with history of cardiomyopathy controlled on cardiac medications. She was taken off study. No additional intervention required. On 3-mo follow-up echo, EF was 44%. This study is supported by Roche-Genentech. 
